Background
Avian influenza A (H7N9) viral pneumonia can manifest with varying degrees of dyspnea and is associated with a mortality of ~30% [
1]. In particular, 97% of patients develop rapidly progressive pneumonia and 71% progress to acute respiratory distress syndrome (ARDS). The mortality of severe ARDS is as high as 62% [
2].
Timely and effective respiratory support is particularly important to treat severe ARDS caused by avian influenza A (H7N9) pneumonia. However, severe ARDS induced by avian influenza A (H7N9) pneumonia might manifest as refractory hypoxaemia even with appropriate invasive positive pressure ventilation (IPPV) support. Extracorporeal membrane oxygenation (ECMO) is the ultimate respiratory support method and directly improves the oxygenation and ventilation of patients as well as enables implementation of the “lung protective ventilation strategy” [
3]. ECMO was the breakthrough treatment for the severe avian influenza A (H1N1) outbreak of 2009 and reduced mortality from this outbreak [
4‐
6]. Therefore, we believe that ECMO could also be effective for other types of severe viral pneumonia.
Existing studies of ECMO treatment for avian influenza A (H7N9) pneumonia are primarily limited to case reports [
7‐
9], and no study has systematically reviewed the efficacy or safety of ECMO to treat such diseases. Therefore, it is particularly important to understand the current application of ECMO for avian influenza A (H7N9) pneumonia-induced severe ARDS, investigate the application timing and management strategies of ECMO, and explore the possible reasons for treatment failure. Based on the current study, we expect to standardize the management of ECMO and provide a description of our experiences using ECMO to treat patients with avian influenza A (H7N9) pneumonia-induced severe ARDS.
Methods
Study population and data collection
Patients who had laboratory-confirmed avian influenza A (H7N9) virus-induced pneumonia were included in this study. Patients were admitted to 20 hospitals in 9 provinces of China between October 1, 2016, and March 1, 2017, and were reported to the National Health and Family Planning Commission of China.
We included patients aged >14 ys who were supported by ECMO. Patients who were lacking key detailed records of parameters during ECMO, such as ventilator or laboratory findings, were excluded.
The included patients were divided into 2 groups, namely, the “successfully weaned group” and “unsuccessfully weaned group”. The former refers to a group of patients whose condition improved and were weaned from ECMO for at least 48 h; the “unsuccessfully weaned group” refers to those who died or voluntarily discontinued treatment due to lack of improvement during ECMO support.
General conditions
The general conditions included age, gender, pregnancy status, underlying disease, time from onset to antiviral drug administration, vasoactive drug administration pre-ECMO, duration of IPPV pre-ECMO, whether rescue ventilation strategies (including lung recruitment maneuvre, prone-position ventilation, and high-frequency oscillation ventilation) were implemented pre-ECMO, disease severity score, total duration of ECMO and IPPV.
Conditions during ECMO
We collected the ECMO blood flow at 24, 48, 72, and 96 h on ECMO. Improvement in circulatory and respiratory physiological indicators were considered, as well as IPPV parameters at 6 h pre-ECMO and 24, 48, and 72 h on ECMO. Furthermore, anticoagulation indicators during ECMO, including the types of anticoagulant drugs and methods of use; the maximum and minimum values of the activated coagulation time (ACT) and activated partial thromboplastin time (APTT); and the differences between the maximum and minimum ACT and APTT at 24, 48, and 72 h on ECMO were recorded. Finally, data regarding complications during ECMO therapy, including ECMO and IPPV-related complications and nosocomial infections, were collected.
Study definitions and design
Outcomes
The primary outcome was in-hospital mortality. The secondary outcomes were the length of stay in the intensive care unit (ICU) and total length of hospitalization.
Definition of avian influenza A (H7N9) virus infection
Three methods were used for a laboratory diagnosis, namely, the real-time reverse transcription-polymerase chain reaction (RT-PCR), viral isolation, and serological testing for the avian influenza A (H7N9) virus using a modified haemagglutinin inhibition assay [
10‐
12].
Definition of acute respiratory syndrome (ARDS)
We defined ARDS according to the Berlin definition in 2012 [
13,
14].
Definitions of pneumonia and severe pneumonia
Pneumonia was diagnosed as an acute illness with fever, cough, or dyspnea/tachypnea, and at least one new focal chest sign that was supported by a finding of lung shadowing on a chest radiograph and without other non-infectious causes.
The primary criteria for severe pneumonia were as follows: <1 > need for tracheal intubation and mechanical ventilation (MV) and <2 > need for vasoactive drugs after the active fluid resuscitation due to septic shock. The secondary criteria were as follows: <1 > respiratory rate ≥ 30 times/min; <2 > PaO
2/FiO
2 ≤ 250 mmHg; <3 > multiple lobe infiltration; <4 > disturbances of consciousness, disorientation, or both; <5 > blood urea nitrogen ≥ 7.14 mmol/L; and <6 > systolic blood pressure ≤ 90 mmHg that required active fluid resuscitation. Patients who met one primary criterion or at least three secondary criteria were diagnosed as having severe pneumonia [
15].
Definitions of ventilator-associated pneumonia (VAP)
The criteria for the diagnosis of VAP are in accordance with the European Centre for Disease Prevention and Control [
16] and included the following: <1 > two or more sequential chest x-rays or CT scans with a suggestive image of pneumonia for patients with underlying cardiac or pulmonary disease, or one definitive chest x-ray or CT scan in patients without underlying cardiac or pulmonary disease; <2 > a fever greater than 38 °C and/or leukocytosis greater than or equal to 12,000 WBC/mm
3 or leukopenia less than or equal to 4000 WBC/mm
3; and <3 > at least one of the following: <a > new onset of purulent sputum or change in the characteristics of the sputum; <b > cough, dyspnea, or tachycardia; <c > auscultatory findings, such as rales, bronchial breath sounds, ronchi, or wheezing; or <d > worsening gas exchange (e.g., oxygen desaturation or increased oxygen requirements or increased ventilation demand).
For all included patients, we first described the general conditions, ECMO model and parameters, IPPV parameters, the changes in circulation and respiratory physiological indicators from pre-ECMO to on ECMO status, anticoagulation on ECMO, and complications during ECMO therapy in all included patients. Then, we compared patients who were successfully or unsuccessfully weaned from ECMO with regard to above items.
Statistical analysis
All of the analyses were performed using SPSS 17.0 software. Normally distributed continuous variables are expressed as the means ± SD and were compared using the t-test or chi-square test. Non-normally distributed continuous variables are expressed as medians and quartiles and were compared using the Wilcoxon rank-sum test. Categorical variables were compared using the x2 test. P-values < 0.05 were considered significant.
Discussion
This study was the first to systematically and comprehensively discuss as well as elaborate on the current application of the efficacy and safety of ECMO in patients with H7N9 pneumonia-related ARDS.
A few studies [
17,
20,
21,
22] have shown that the mortality of pH1N1-induced ARDS was reduced to 21–61% following ECMO treatment. Presently, no studies with large samples have investigated the mortality of H7N9-induced ARDS, while the in-hospital mortality was as high as 63% in our study. Late initiation of ECMO, inappropriate IPPV settings during ECMO, and more ECMO complications might explain the relatively high mortality. Moreover, as a multicentre collaboration study, the experiences of ECMO varied among the centres (Additional file
4), which might be another reason for the high mortality.
According to the Extracorporeal Life Support Organization (ELSO) data [
23,
24], ECMO is indicated when death risk exceeds 80%, i.e., when PaO
2/FiO
2 < 80 mmHg on FiO
2 > 90% and the Murray score is 3–4. Our patients met the indications for ECMO support. The duration of MV for more than 7 days pre-ECMO is an important prognostic factor for death [
25]. For patients in the successfully weaned group, the duration of IPPV pre-ECMO was 5 ± 1 d; however, the duration was even longer among patients in the unsuccessfully weaned group (6 ± 4 d). Moreover, rescue ventilation strategies were implemented for most patients before ECMO, which partially delayed the timing of ECMO. In comparison, ECMO was initiated at 2 h (1–5 h) after IPPV among patients with pH1N1 in Australia and New Zealand in 2009 [
5], which was significantly shorter than that in our cases. Therefore, we emphasized early implementation of ECMO in our patients.
The principle of IPPV during ECMO is the “lung rest strategy” [
26]. The REVA registry study examined 123 patients with pH1N1-induced ARDS [
6] and showed that the high P
plat (29 cmH
2O) on day 1 of ECMO was related to high mortality. In our study, the pre-ECMO P
plat level was high (29 ± 8 cmH
2O). High P
plat can lead to overdistension of the alveoli and cause lung volutrauma. The shear force between the overdistended and collapsed alveoli further aggregates VILI [
27], which ultimately increases mortality. Although the P
plat values decreased to different degrees after ECMO, the P
plat of the unsuccessfully weaned group was significantly higher at 48 and 72 h during ECMO. The principle of low VT was similar in that we found a lower VT during ECMO in the successfully weaned group. A retrospective observational study of 168 patients with severe ARDS [
28] showed that a high PEEP level within 3 d of being on ECMO was related to decreased mortality. Although no difference was observed in the PEEP levels between the two groups, we speculated that the down-regulation of PEEP during ECMO might have further aggravated the occurrence of collapse-induced injury, which led to atelectasis and sputum discharge obstacles. Therefore, the IPPV parameters, including high P
plat and VT levels and low PEEP settings, might have been unreasonable in our study; lung rest or the maintenance of open alveoli was not achieved.
The incidence of an ECMO oxygenator thrombus, haemorrhage, and organ failure in our study was high, which suggests that some problems existed in the anticoagulation management and organ supportive treatment of ECMO. We found that the unsuccessfully weaned group had larger fluctuations in ACT (the difference between ACTmax and ACTmin were larger) during the early stage of anticoagulation. This effect might suggest relatively unstable anticoagulation and a higher risk of haemorrhage. Moreover, the incidence rate of VAP during ECMO was as high as 60% and was partially attributed to the long course of H7N9 pneumonia and the prolonged duration of IPPV. Therefore, intensification of airway management was extremely necessary.
Our study had limitations. The nature of the study required the collection of data at multiple consecutive time points to evaluate the efficacy of ECMO. As a retrospective study with some missing data, we were unable to successfully collect data at 6 h pre-ECMO and 24, 48, and 72 h post-ECMO. Additionally, the number of subjects was too small to perform a multiple regression analysis to explore the risk factors for unsuccessful weaning from ECMO.